Trial Profile
A Real World Study Evaluating the Outcomes of Ixazomib, Lenalidomide and Dexamethasone (IRD) in Patients with Relapsed and Refractory Multiple Myeloma from a Compassionate Named Patient Program
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 04 Feb 2019
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Ixazomib (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Expanded access; Therapeutic Use
- 29 Jul 2018 New trial record
- 17 Jun 2018 Results (n=118) presented at the 23rd Congress of the European Haematology Association.